Cargando…

Understanding of prognosis in non-metastatic prostate cancer: a randomised comparative study of clinician estimates measured against the PREDICT prostate prognostic model

PREDICT Prostate is an individualised prognostic model that provides long-term survival estimates for men diagnosed with non-metastatic prostate cancer (www.prostate.predict.nhs.uk). In this study clinician estimates of survival were compared against model predictions and its potential value as a cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thurtle, David R., Jenkins, Valerie, Pharoah, Paul D., Gnanapragasam, Vincent J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889281/ https://www.ncbi.nlm.nih.gov/pubmed/31523057 http://dx.doi.org/10.1038/s41416-019-0569-4

Ejemplares similares

Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe)
por: Thurtle, David, et al.
Publicado: (2020)

Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model
por: Thurtle, David R., et al.
Publicado: (2019)

Models predicting survival to guide treatment decision-making in newly diagnosed primary non-metastatic prostate cancer: a systematic review
por: Thurtle, David, et al.
Publicado: (2019)

Composite risk stratification models optimise the value of imaging in prostate cancer staging
por: McAllister, Tom, et al.
Publicado: (2023)

Improving the safety and tolerability of local anaesthetic outpatient transperineal prostate biopsies: A pilot study of the CAMbridge PROstate Biopsy (CAMPROBE) method
por: Thurtle, D, et al.
Publicado: (2018)

Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer
por: Liu, Shiqin, et al.
Publicado: (2020)

Rates of Positive Abdominal Computed Tomography and Bone Scan Findings Among Men with Cambridge Prognostic Group 4 or 5 prostate cancer: A Nationwide Registry Study
por: Stenman, Caroline, et al.
Publicado: (2022)

Incorporating multiparametric MRI staging and the new histological Grade Group system improves risk-stratified detection of bone metastasis in prostate cancer
por: Thurtle, David, et al.
Publicado: (2016)

Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer
por: Severson, Tesa, et al.
Publicado: (2022)

Novel concepts for risk stratification in prostate cancer
por: Patel, Keval M, et al.
Publicado: (2016)

Developing machine learning algorithms for dynamic estimation of progression during active surveillance for prostate cancer
por: Lee, Changhee, et al.
Publicado: (2022)

Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
por: Arnold, Peter, et al.
Publicado: (2021)

Trends and Outcome from Radical Therapy for Primary Non-Metastatic Prostate Cancer in a UK Population
por: Greenberg, David C., et al.
Publicado: (2015)

The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study
por: Gnanapragasam, V. J., et al.
Publicado: (2018)

Geriatric Assessment Implementation before Chemotherapy in MEtastatic Prostate Cancer, Results from the Real-Life Study GAMERS
por: Gluszak, Cassandre, et al.
Publicado: (2023)

The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.
por: Fosså, S. D., et al.
Publicado: (1992)

Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study
por: Gnanapragasam, Vincent J., et al.
Publicado: (2016)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)

Prognostic value of genomic mutations in metastatic prostate cancer()()
por: Zhu, Honghui, et al.
Publicado: (2023)

Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer
por: Hermanova, Ivana, et al.
Publicado: (2020)

Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician’s Perspective
por: Matsumoto, Takashi, et al.
Publicado: (2022)

Editorial: Metastatic Castration Resistant Prostate Cancer: Prognosis and Treatment
por: Muniyan, Sakthivel, et al.
Publicado: (2022)

Liquid Biopsy in Diagnosis and Prognosis of Non-Metastatic Prostate Cancer
por: Rzhevskiy, Alexey S., et al.
Publicado: (2022)

Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel
por: Halabi, Susan, et al.
Publicado: (2020)

Impact of COVID‐19 on the incidence of localized and metastatic prostate cancer among White and Black Veterans
por: Lee, Kyung Min, et al.
Publicado: (2022)

Expression of SPANX proteins in normal prostatic tissue and in prostate cancer
por: Salemi, M., et al.
Publicado: (2010)

Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients
por: Kesavan, Murali, et al.
Publicado: (2021)

(177)Lu-Prostate-Specific Membrane Antigen Ligand After (223)Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience
por: Sartor, Oliver, et al.
Publicado: (2022)

Safety and Survival Outcomes of (177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior (223)Ra treatment: The RALU Study
por: Rahbar, Kambiz, et al.
Publicado: (2023)

The Prognostic Nutritional Index (PNI): A New Biomarker for Determining Prognosis in Metastatic Castration-Sensitive Prostate Carcinoma
por: Ellez, Halil Ibrahim, et al.
Publicado: (2023)

Analysis of Circulating Immune Biomarkers by Race in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Sipuleucel-T
por: Hawley, Jessica E, et al.
Publicado: (2021)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
por: Fujmoto, Saizo, et al.
Publicado: (2022)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
por: Tzeng, Michael, et al.
Publicado: (2021)

Invasive characteristics of human prostatic epithelial cells: understanding the metastatic process
por: Hart, C A, et al.
Publicado: (2005)

An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer
por: Saxby, Helen, et al.
Publicado: (2020)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
por: Mizokami, Atsushi, et al.
Publicado: (2017)

Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer
por: Nyame, Yaw A, et al.
Publicado: (2020)

Tuberculous prostatitis mimicking metastatic prostate cancer
por: Aslan, Serdar, et al.
Publicado: (2022)

Urinary symptoms and prostate cancer—the misconception that may be preventing earlier presentation and better survival outcomes
por: Gnanapragasam, Vincent J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n1i92oni7fbvkm3kt922k2tef0